Status:
UNKNOWN
Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment
Lead Sponsor:
Hunt Regional Medical Center
Conditions:
SARS-CoV-2
Hypoxia
Eligibility:
All Genders
18-100 years
Phase:
EARLY_PHASE1
Brief Summary
Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular re...
Detailed Description
We are investigating in prospective ongoing non-randomized case study effects of addition of dapsone 100-200 mg daily in addition to standardized recommended treatment versus a a cohort of patient adm...
Eligibility Criteria
Inclusion
- 1\. All, PCR confirmed cases of COVID-19
Exclusion
- 1\. Only consenting consenting patients
- \-
Key Trial Info
Start Date :
October 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04918914
Start Date
October 18 2020
End Date
December 31 2021
Last Update
June 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunt Regional Medical Center
Greenville, Texas, United States, 75401